吉瑞替尼联合化疗治疗初诊FLT3突变阳性急性髓系白血病的疗效与安全性
回顾性收集江苏省人民医院16例初诊FLT3突变阳性AML患者,接受「3+7」或VA方案诱导并加用吉瑞替尼。首周期CR/CRi率93.8%(15/16),12个月总生存率和无复发生存率均为73.9%,治疗相关不良反应总体可耐受。
要点
- 首周期吉瑞替尼联合诱导CR/CRi率93.8%(15/16),13例流式检测MRD阴性。
- 巩固期所有患者达CR(MRD-),14例二代测序均达FLT3突变阴性。
- 中位随访18个月,12个月总生存率与无复发生存率均为73.9%。
核心结论
- 吉瑞替尼联合化疗治疗初诊FLT3突变阳性AML的完全缓解率高,治疗相关不良反应总体可耐受。
研究设计与样本
- 回顾性收集江苏省人民医院16例初诊FLT3突变阳性AML患者的临床资料。
- 患者接受经典「3+7」方案或VA(维奈克拉+阿扎胞苷)方案诱导治疗,检出FLT3-ITD/TKD突变后加用吉瑞替尼。
- 16例中男12例、女4例,中位年龄52.5(15~76)岁;FLT3-ITD突变15例,FLT3-TKD突变1例。
主要发现
- 首周期吉瑞替尼联合诱导后CR/CRi率93.8%(15/16),其中13例流式细胞术检测MRD阴性。
- 巩固治疗期间所有患者均达到CR(MRD-),14例进行二代测序检测并均达FLT3突变阴性。
- 截至2024年5月,中位随访18个月,12个月总生存率和无复发生存率均为73.9%。
- 诱导期间9例(56.2%)患者出现感染性发热,巩固与维持治疗期间3例发生3级QTc延长。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study aimed to assess the efficacy and safety of gilteritinib combined with chemotherapy in treating newly diagnosed FLT3-mutated acute myeloid leukemia (AML). We retrospectively collected clinical data from 16 patients newly diagnosed with FLT3-mutated AML at Jiangsu Province Hospital. Patients received induction therapy with the classic "3 + 7" regimen or the VA regimen, and all patients were immediately supplied with gilteritinib after detecting FLT3-ITD/TKD mutations. Of the 16 patients, 12 were male and 4 were female, with a median age of 52.5 years (range: 15-76 years). Additionally, 15 patients had FLT3-ITD mutations and 1 had FLT3-TKD mutation. The complete remission (CR/CRi) rate was 93.8% (15/16) after the first cycle of gilteritinib-based induction therapy, with 13 patients achieving MRD negativity detected with flow cytometry. All patients achieved a CR(MRD-) during the consolidation phase. FLT3 mutation clearance was achieved among all 14 patients who underwent next-generation sequencing (NGS) analysis. The 12-month overall survival and relapse-free survival rates were both 73.9%, respectively, with a median followup of 18 months. Nine (56.2%) patients experienced infectious fever during the induction therapy. Three patients had grade 3 QTc prolongation during consolidation and maintenance therapy. Treatment-related adverse events were generally tolerable. 为评估吉瑞替尼联合化疗治疗初诊FLT3突变阳性急性髓系白血病(AML)的疗效与安全性,我们回顾性收集于江苏省人民医院就诊的16例初诊FLT3突变阳性AML患者的临床资料。患者接受经典"3+7"方案或VA(维奈克拉+阿扎胞苷)方案诱导治疗,并均在检出FLT3-ITD/TKD突变后加用吉瑞替尼。16例患者中,男12例,女4例,中位年龄为52.5(15~76)岁;FLT3-ITD突变15例,FLT3-TKD突变1例。经过1个周期治疗后,完全缓解(CR)/CR伴不完全血细胞恢复(CRi)率达到93.8%(15/16),其中13例患者达到流式细胞术检测的可检测残留病(MRD)阴性。巩固治疗期间所有患者均达到CR(MRD-),14例进行二代测序检测并均达FLT3突变阴性。截至2024年5月,中位随访时间为18个月,12个月总生存率和无复发生存率均为73.9%。诱导期间9例(56.2%)患者出现感染性发热,巩固与维持治疗期间3例患者发生3级QTc延长,治疗相关不良反应总体可耐受。.
引用
- Lei YT, Zhao XL, Hong M, et al. [Efficacy and safety of gilteritinib combined with chemotherapy in newly diagnosed FLT3-mutated acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 39765355. doi:10.3760/cma.j.cn121090-20240615-00224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。